American Society of Clinical OncologyAppropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update

An update from the original ASCO guideline on this topic published in 2012, 60 studies, primarily retrospective, were included in the review. New to this version of the guideline, the Panel offers recommendations on approved doses of immunotherapy and targeted therapies that can be offered to obese patients with cancer.

American Society of HematologyASH 2021 Guidelines for Management of Venous Thromboembolism: Prevention and Treatment in Patients with Cancer

These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of venous thromboembolism (VTE)  – a common complication among patients with cancer who are at a markedly increased risk for morbidity and mortality.

American Society of HematologyASH/ISTH/NHF/WFH 2021 Guidelines on the Management of von Willebrand Disease

These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of von Willebrand Disease (VWD), a common inherited bleeding disorder.

HMP CommunicationsASCO Updates Guideline on Early Breast Cancer Treatment

The American Society of Clinical Oncology (ASCO) published a guideline update about the selection of optimal adjuvant chemotherapy regimens and targeted therapy for early breast cancer, namely trastuzumab emtansine. In a second recommendation, the ASCO guideline addressed the use of biosimilar forms of trastuzumab—five of which have been approved by the FDA.

American Society of HematologyASH 2020 Guidelines: Treatment of Deep Vein Thrombosis and Pulmonary Embolism

The American Society of Hematology (ASH) used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence and make recommendations toward the treatment of venous thromboembolism (VTE). The panel agreed on 28 recommendations for the initial management of VTE, primary treatment, secondary prevention, and treatment of recurrent VTE events.

American Society of HematologyASH 2020 Guidelines for Treating Newly Diagnosed AML in Older Adults

Older adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations. Discover what the American Society of Hematology (ASH) recommends for your older adult AML patients.